---
title: "City | 8-K: FY2026 Q2 Revenue: USD 81.52 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293493509.md"
datetime: "2026-07-22T15:23:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293493509.md)
  - [en](https://longbridge.com/en/news/293493509.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293493509.md)
generator: "portal-rs"
---

# City | 8-K: FY2026 Q2 Revenue: USD 81.52 M

Revenue: As of FY2026 Q2, the actual value is USD 81.52 M.

EPS: As of FY2026 Q2, the actual value is USD 2.35, beating the estimate of USD 2.226.

EBIT: As of FY2026 Q2, the actual value is USD 41.32 M.

The provided reference, a FORM 8-K filing by City Holding Company dated July 22, 2026, indicates that the company issued a news release announcing its earnings results for the second quarter ended June 30, 2026. However, the actual financial and operational metrics, as well as any outlook or guidance from this news release, are not included within the provided text of the 8-K filing. Therefore, no specific financial or operational metrics, or outlook, can be extracted from this reference.

### Related Stocks

- [CHCO.US](https://longbridge.com/en/quote/CHCO.US.md)

## Related News & Research

- [7,428 Shares in City Holding Company $CHCO Acquired by Susquehanna Fundamental Investments LLC](https://longbridge.com/en/news/297761849.md)
- [Weekly Recap: 1.5M-share inducement grant and furnished Form 8-K PSU award](https://longbridge.com/en/news/298207980.md)
- [REG - General Elec. - Doc re. GE Files 8-K](https://longbridge.com/en/news/298321667.md)
- [BioRestorative amends 8-K to clarify auditor change, audit committee probe scope](https://longbridge.com/en/news/298641440.md)
- [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**